ArticleAnnals of clinical and translational neurology2026
Ofatumumab Therapy and Long-Term Seizure Outcomes of Patients With Relapsing Anti-NMDA Receptor Encephalitis.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThere is a lack of studies on seizure outcomes associated with ofatumumab therapy in patients for relapsing anti-N-methyl-D-aspartate (NMDA) receptor encephalitis. We aimed to evaluate long-term seizure outcomes of ofatumumab therapy for relapsing anti-NMDA receptor encephalitis.
methodsThis is a prospective cohort study, Compared patients with relapsing anti-NMDA receptor encephalitis who had received at least 1 ofatumumab dose and a control cohort of non-ofatumumab-treated patients, continuous follow-up for 24 months. The primary outcome was the seizure outcomes (including both seizure reduction and seizure freedom; seizure reduction is defined as a reduction in seizure frequency to 50% or more of the baseline level, seizure freedom is defined as having no seizures) at the follow-up. The secondary outcomes included modified Rankin Scale (mRS) scores and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores over the 24-month follow-up.
resultsWe enrolled 93 patients with relapsing anti-NMDA receptor encephalitis. A total of 76 patients met the requirements after the inclusion and exclusion criteria. The 38 patients received ofatumumab therapy, and the other 38 patients received non-ofatumumab therapy. Follow-up after 6 months, the ofatumumab therapy group demonstrated favorable seizure outcomes (63.16% vs. 36.84%, p < 0.05). Follow-up after 12 months, this improvement of seizure outcomes was more pronounced (78.95% vs. 60.53%, p < 0.05). Follow-up after 24 months, this difference between the two groups widened further (94.74% vs. 78.95%, p < 0.05), compared with the non-ofatumumab therapy group. Follow-up after 6 months, the ofatumumab group demonstrated a faster mRS scores (2.85 ± 0.65 vs. 3.75 ± 0.55, p < 0.05) and CASE scores (11.80 ± 1.65 vs. 13.75 ± 1.55, p < 0.05). Follow-up after 12 months, the ofatumumab group demonstrated a faster mRS scores (1.68 ± 0.45 vs. 2.39 ± 0.35, p < 0.05) and CASE scores (6.75 ± 1.45 vs. 9.39 ± 1.35 p < 0.05). Follow-up after 24 months, the ofatumumab group demonstrated a faster mRS scores (1.25 ± 0.35 vs. 1.68 ± 0.45, p < 0.05) and CASE scores (4.25 ± 0.75 vs. 6.68 ± 1.35, p < 0.05). And no serious adverse events associated with ofatumumab treatment were reported. Furthermore, Multivariate logistic regression analysis identified that early initiation of ofatumumab therapy, psychiatric symptoms, and abnormal brain MRI findings may be associated with seizure outcomes.
conclusionsOfatumumab showed substantial improvement in long-term seizure outcomes in patients with relapsing anti-NMDA receptor encephalitis, particularly those presenting with seizures as a predominant clinical feature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.